Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

- PMLiVE

Imbruvica and Gazyvo approved in first non-chemo CLL use

Further boost for blockbuster leukaemia drug

- PMLiVE

Hardy returns to Genentech as CEO

In other news, Vertex fires chief operating officer

- PMLiVE

Vertex gains EU approval for earlier Orkambi use

Cystic Fibrosis drug approved in children aged 2-5 years

- PMLiVE

Europe closer to biosimilar rule change, despite fierce resistance from pharma

EFPIA says it weakens IP commitment - supporters say it will boost exports

- PMLiVE

NICE gives Lilly’s Verzenios chance to compete with rivals

Breast cancer drug also being appraised in novel combination

- PMLiVE

Crunch time as Brexit deal faces ‘meaningful vote’

Rejecting the deal would either result in a no deal or no Brexit, warns May

- PMLiVE

Time running out for ‘no-deal’ Brexit medicines laws

Needs parliament clearance before 29 March

- PMLiVE

Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

FDA takes aim at pharma’s biosimilar-delaying tactics

Ever-rising cost of insulins also to be targeted

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

- PMLiVE

Shire’s angioedema drug Takhzyro claims EU approval

Approval shortly follows a green light in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links